A multicenter randomized controlled clinical study of rituximab or in combination with human immunoglobulin in the treatment of severe pemphigus

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100042025

Enrollment

Unknown

Registered

2021-01-12

Start date

2019-04-01

Completion date

Unknown

Last updated

2021-04-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pemphigus vulgaris/foliaceus

Interventions

GroupA:RTX1000mg+IVIG+GC0.5-1mg/kg/d

GroupB:RTX500mg+IVIG+GC0.5-1mg/kg/d

GroupC:RTX500mg+GC0.5-1mg/kg/d

GroupD:Standard treatment plan

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients aged 18-80 years old; 2. Patients who have been diagnosed with pemphigus; 3. Patients with pdai score > 25; 4. Patients with stable vital signs; 5. Patients receiving rituximab for the first time; 6. The subjects who have signed the informed consent and can obey the clinical research protocol.

Exclusion criteria

Exclusion criteria: 1. Patients who have received RTX or RTX treatment for recurrence in the past; 2. Patients with drug contraindications include severe cardiovascular disease, severe liver and kidney damage, severe active infection, severe transfusion reaction in the past, history of severe allergy to related drugs, history of tumor, pregnant women and lactating women, recent vaccination or planned vaccination.

Design outcomes

Primary

Measure	Time frame
PDAI;Peripheral blood lymphocyte;DSG1;DSG3;Glucocorticoid dosage;	—

Countries

China

Contacts

Public ContactChen Yongfeng

Dermatology Hospital of Southern Medical University

gdcyf@163.com+86 13802920269

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026